Quantum Biosciences Named Winner at NASSCOM Emerge 50 Awards in Healthtech & Life Sciences
Recognized in India's flagship deep-tech benchmark for pioneering quantum-enabled cellular diagnostics and predictive organ injury sensing.
Quantum Biosciences (QBS) has been officially named an award winner in the prestigious NASSCOM Emerge 50 (2026) awards, securing top honors in the competitive Healthtech & Life Sciences category. The recognition underscores QBS's breakthrough approach of interfacing quantum spin relaxometry with cellular physiology to predict acute organ injury before irreversible damage occurs.
About the NASSCOM Emerge 50 Benchmark
For over 15 years, the NASSCOM Emerge 50 initiative has served as India's most coveted benchmark for identifying and spotlighting high-potential, IP-driven deep-tech startups. The awards evaluate enterprise and product companies transforming India from a technology consumer into a global technology creator.
Evaluation is conducted by a distinguished jury of senior technologists, clinical experts, and venture leaders who scrutinize deep technical moats, intellectual property defensibility, scientific scalability, and market impact. Past winners of the Emerge 50 cohort have collectively raised billions in growth capital and pioneered foundational technologies worldwide.
The Breakthrough: Quantum Sentinel™ in Real-Time Diagnostics
Standard diagnostic blood tests and metabolic panels measure lagging markers of clinical injury—such as serum creatinine or transaminases—that only surge hours or days after extensive tissue necrosis has already occurred. By that stage, doctors are reacting to damage that is already permanent.
Quantum Biosciences is transforming this paradigm through its flagship Quantum Sentinel™ platform. By deploying microscopic, biocompatible diamond sensors containing nitrogen-vacancy (NV) spin defects, the platform measures free-radical surges and sub-cellular metabolic distress in real time.
This enables clinicians to detect acute organ stress hours before irreversible cell death, providing a critical therapeutic window to intervene during major surgeries, organ transplants, and intensive care admissions.
“Our mission is to end the diagnostic blind spot in acute care medicine. Being recognized in the NASSCOM Emerge 50 cohort affirms the tremendous dedication of our multidisciplinary team bridging physics, biology, and machine learning.”
Incubation at C-CAMP and Institutional Backing
Headquartered and incubated at the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, Quantum Biosciences operates at the epicenter of India's bio-innovation ecosystem.
The company's translational research is strategically supported by the Government of India's National Quantum Mission (NQM) and Ministry of Electronics and Information Technology (MeitY), accelerating the transition of room-temperature quantum bio-sensing from laboratory physics to regulated clinical instrumentation.